• Something wrong with this record ?

Imaging Biomarkers in Prodromal and Earliest Phases of Parkinson's Disease

H. Theis, N. Pavese, I. Rektorová, T. van Eimeren

. 2024 ; 14 (s2) : S353-S365. [pub] -

Language English Country Netherlands

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc25004206

Assessing imaging biomarker in the prodromal and early phases of Parkinson's disease (PD) is of great importance to ensure an early and safe diagnosis. In the last decades, imaging modalities advanced and are now able to assess many different aspects of neurodegeneration in PD. MRI sequences can measure iron content or neuromelanin. Apart from SPECT imaging with Ioflupane, more specific PET tracers to assess degeneration of the dopaminergic system are available. Furthermore, metabolic PET patterns can be used to anticipate a phenoconversion from prodromal PD to manifest PD. In this regard, it is worth mentioning that PET imaging of inflammation will gain significance. Molecular imaging of neurotransmitters like serotonin, noradrenaline and acetylcholine shed more light on non-motor symptoms. Outside of the brain, molecular imaging of the heart and gut is used to measure PD-related degeneration of the autonomous nervous system. Moreover, optical coherence tomography can noninvasively detect degeneration of retinal fibers as a potential biomarker in PD. In this review, we describe these state-of-the-art imaging modalities in early and prodromal PD and point out in how far these techniques can and will be used in the future to pave the way towards a biomarker-based staging of PD.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25004206
003      
CZ-PrNML
005      
20250206110016.0
007      
ta
008      
250121s2024 ne f 000 0|eng||
009      
AR
024    7_
$a 10.3233/JPD-230385 $2 doi
035    __
$a (PubMed)38339941
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Theis, Hendrik $u University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Nuclear Medicine, Multimodal Neuroimaging Group, Cologne, Germany $u University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, Cologne, Germany
245    10
$a Imaging Biomarkers in Prodromal and Earliest Phases of Parkinson's Disease / $c H. Theis, N. Pavese, I. Rektorová, T. van Eimeren
520    9_
$a Assessing imaging biomarker in the prodromal and early phases of Parkinson's disease (PD) is of great importance to ensure an early and safe diagnosis. In the last decades, imaging modalities advanced and are now able to assess many different aspects of neurodegeneration in PD. MRI sequences can measure iron content or neuromelanin. Apart from SPECT imaging with Ioflupane, more specific PET tracers to assess degeneration of the dopaminergic system are available. Furthermore, metabolic PET patterns can be used to anticipate a phenoconversion from prodromal PD to manifest PD. In this regard, it is worth mentioning that PET imaging of inflammation will gain significance. Molecular imaging of neurotransmitters like serotonin, noradrenaline and acetylcholine shed more light on non-motor symptoms. Outside of the brain, molecular imaging of the heart and gut is used to measure PD-related degeneration of the autonomous nervous system. Moreover, optical coherence tomography can noninvasively detect degeneration of retinal fibers as a potential biomarker in PD. In this review, we describe these state-of-the-art imaging modalities in early and prodromal PD and point out in how far these techniques can and will be used in the future to pave the way towards a biomarker-based staging of PD.
650    12
$a Parkinsonova nemoc $x diagnostické zobrazování $x metabolismus $x diagnóza $7 D010300
650    _2
$a lidé $7 D006801
650    12
$a prodromální symptomy $7 D062706
650    12
$a biologické markery $x metabolismus $x analýza $7 D015415
650    _2
$a optická koherentní tomografie $x metody $7 D041623
650    _2
$a pozitronová emisní tomografie $7 D049268
650    _2
$a neurozobrazování $x metody $7 D059906
650    _2
$a magnetická rezonanční tomografie $7 D008279
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Pavese, Nicola $u Aarhus University, Institute of Clinical Medicine, Department of Nuclear Medicine & PET, Aarhus N, Denmark $u Newcastle University, Translational and Clinical Research Institute, Newcastle upon Tyne, United Kingdom
700    1_
$a Rektorová, Irena $u Masaryk University, Faculty of Medicine and St. Anne's University Hospital, International Clinical Research Center, ICRC, Brno, Czech Republic $u Masaryk University, Faculty of Medicine and St. Anne's University Hospital, First Department of Neurology, Brno, Czech Republic $u Masaryk University, Applied Neuroscience Research Group, Central European Institute of Technology - CEITEC, Brno, Czech Republic
700    1_
$a van Eimeren, Thilo $u University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Nuclear Medicine, Multimodal Neuroimaging Group, Cologne, Germany $u University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, Cologne, Germany
773    0_
$w MED00208289 $t Journal of Parkinson's disease $x 1877-718X $g Roč. 14, s2 (2024), s. S353-S365
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38339941 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206110012 $b ABA008
999    __
$a ok $b bmc $g 2263756 $s 1240213
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 14 $c s2 $d S353-S365 $e - $i 1877-718X $m Journal of Parkinson's disease $n J Parkinsons Dis $x MED00208289
LZP    __
$a Pubmed-20250121
Back

Find record

Citation metrics

Archiving options